Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03105271 · ClinicalTrials.gov registry record
Acute Kidney Injury in Patients With Sickle Cell Disease
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 60
- Enrollment target
NCT03105271 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants.
The verdict
NCT03105271 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
Patients with sickle cell disease may be at risk for acute kidney injury (AKI)during sickle cell crisis (pain or acute chest syndrome). This study will evaluate the role of hemolysis during SCD crisis on the development of AKI and the role for monitoring urine biomarkers during an admission for crisis and during well clinic follow-up.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2022-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03105271
The ClinicalTrials.gov registry entry for NCT03105271 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03105271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03105271 about?
NCT03105271 is a clinical study titled "Acute Kidney Injury in Patients With Sickle Cell Disease". Patients with sickle cell disease may be at risk for acute kidney injury (AKI)during sickle cell crisis (pain or acute chest syndrome). This study will evaluate the role of hemolysis during SCD crisis on the development of AKI and the role for monitoring urine biomarkers during an admission for cris...
What is the current status of trial NCT03105271?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2017-01-01. Estimated completion is 2022-01-31.
Who is sponsoring clinical trial NCT03105271?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.